$YTENQ
YIELD10 BIOSCIENCE, INC.

2018 Q2 Form 10-Q Financial Statement

#000112170218000016 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $285.0K $60.00K $324.0K
YoY Change -2.73% -81.48% 106.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.456M $1.276M $1.276M
YoY Change -21.97% 0.0% -43.84%
% of Gross Profit
Research & Development $1.260M $1.100M $1.110M
YoY Change 10.53% -0.9% -22.38%
% of Gross Profit
Depreciation & Amortization $50.00K $47.00K $53.00K
YoY Change -16.67% -11.32% -56.56%
% of Gross Profit
Operating Expenses $1.456M $1.276M $1.276M
YoY Change -21.97% 0.0% -43.84%
Operating Profit -$2.431M -$2.317M -$2.061M
YoY Change -10.33% 12.42% -41.83%
Interest Expense -$30.00K
YoY Change -1100.0%
% of Operating Profit
Other Income/Expense, Net $38.00K $25.00K -$31.00K
YoY Change -337.5% -180.65% -1133.33%
Pretax Income -$2.390M -$2.290M -$2.090M
YoY Change -12.45% 9.57% -40.96%
Income Tax
% Of Pretax Income
Net Earnings -$2.393M -$2.292M -$2.090M
YoY Change -12.34% 9.67% -67.85%
Net Earnings / Revenue -839.65% -3820.0% -645.06%
Basic Earnings Per Share
Diluted Earnings Per Share -$9.560M -$9.542M -$29.86M
COMMON SHARES
Basic Shares Outstanding 9.968M shares 28.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.700M $11.60M $4.900M
YoY Change 223.33% 136.73% -7.55%
Cash & Equivalents $3.168M $7.583M $4.875M
Short-Term Investments $6.500M $4.000M
Other Short-Term Assets $400.0K $400.0K $500.0K
YoY Change -20.0% -20.0% -73.68%
Inventory
Prepaid Expenses
Receivables $29.00K $42.00K $210.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $10.10M $12.09M $5.659M
YoY Change 158.55% 113.71% -30.13%
LONG-TERM ASSETS
Property, Plant & Equipment $1.477M $1.526M $1.686M
YoY Change -9.55% -9.49% 24.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $98.00K $103.0K $95.00K
YoY Change 3.16% 8.42% -86.75%
Total Long-Term Assets $7.116M $7.240M $2.835M
YoY Change 229.44% 155.38% 13.35%
TOTAL ASSETS
Total Short-Term Assets $10.10M $12.09M $5.659M
Total Long-Term Assets $7.116M $7.240M $2.835M
Total Assets $17.22M $19.33M $8.494M
YoY Change 183.78% 127.62% -19.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.00K $80.00K $51.00K
YoY Change -51.43% 56.86% -71.82%
Accrued Expenses $871.0K $788.0K $2.536M
YoY Change -67.61% -68.93% -4.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.489M $1.432M $2.587M
YoY Change -46.03% -44.65% -16.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $900.0K $1.000M $1.300M
YoY Change -18.18% -23.08% 303.73%
Total Long-Term Liabilities $900.0K $1.000M $1.300M
YoY Change -18.18% -23.08% 303.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.489M $1.432M $2.587M
Total Long-Term Liabilities $900.0K $1.000M $1.300M
Total Liabilities $2.430M $2.405M $3.933M
YoY Change -36.5% -38.85% 14.87%
SHAREHOLDERS EQUITY
Retained Earnings -$347.4M -$345.0M -$335.4M
YoY Change 2.74% 2.86% 0.96%
Common Stock $357.1M $356.8M $340.1M
YoY Change 4.88% 4.9% 0.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.576M $11.63M $4.561M
YoY Change
Total Liabilities & Shareholders Equity $17.22M $19.33M $8.494M
YoY Change 183.78% 127.62% -19.87%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$2.393M -$2.292M -$2.090M
YoY Change -12.34% 9.67% -67.85%
Depreciation, Depletion And Amortization $50.00K $47.00K $53.00K
YoY Change -16.67% -11.32% -56.56%
Cash From Operating Activities -$1.860M -$3.030M -$2.433M
YoY Change 0.0% 24.54% -62.72%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $3.000K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$2.500M -$3.990M $0.00
YoY Change -100.0%
Cash From Investing Activities -$2.530M -$3.994M $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $124.0K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.860M -$3.030M -$2.433M
Cash From Investing Activities -2.530M -$3.994M $0.00
Cash From Financing Activities 0.000 $124.0K
Net Change In Cash -4.390M -$6.904M -$2.433M
YoY Change 134.76% 183.76% -65.21%
FREE CASH FLOW
Cash From Operating Activities -$1.860M -$3.030M -$2.433M
Capital Expenditures -$30.00K $3.000K $0.00
Free Cash Flow -$1.830M -$3.033M -$2.433M
YoY Change -1.61% 24.66% -63.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001121702
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9968455 shares
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
YIELD10 BIOSCIENCE, INC.
CY2017Q3 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
5.04
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
76000 USD
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
80000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54000 USD
CY2018Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
42000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2299000 USD
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1352000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
335000 USD
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
175000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-85000 USD
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-89000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
355431000 USD
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
356667000 USD
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1031130 shares
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11312467 shares
CY2016Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29622 sqft
CY2017Q4 us-gaap Assets
Assets
16882000 USD
CY2018Q1 us-gaap Assets
Assets
14040000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
14917000 USD
CY2018Q1 us-gaap Assets Current
AssetsCurrent
12094000 USD
CY2018Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
3991 USD
CY2018Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
3990 USD
CY2018Q1 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
1 USD
CY2018Q1 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0 USD
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14487000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7583000 USD
CY2018Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
11574000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
10597486 shares
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12180541 shares
CY2018Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11323863 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9089159 shares
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9968455 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9089159 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9968455 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
91000 USD
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2093000 USD
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2294000 USD
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
2385000 USD
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
2367000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
53000 USD
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
47000 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000 USD
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-4000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
646000 USD
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
276000 USD
CY2017 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.25
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-27000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
144000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-12000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-168000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-971000 USD
CY2017Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-1000 USD
CY2018Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
0 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
97000 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
125000 USD
CY2017Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-7000 USD
CY2018Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-29000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
3380000 USD
CY2018Q1 us-gaap Liabilities
Liabilities
2405000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16882000 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14040000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2375000 USD
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1432000 USD
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2018Q1 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2017Q1 us-gaap Loss On Contract Termination
LossOnContractTermination
2641000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-2434000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-6904000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
124000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3994000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2433000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3030000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2092000 USD
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2290000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2061000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2307000 USD
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
0 USD
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
0 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
829000 USD
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
655000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
109000 USD
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
103000 USD
CY2017Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000 USD
CY2018Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-5000 USD
CY2018Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
35000 USD
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000 USD
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1826 shares
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1826 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4000 USD
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000 USD
CY2017Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
32000 USD
CY2018Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
18000 USD
CY2017Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1000 USD
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000 USD
CY2017Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
317000 USD
CY2017Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1392000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000 USD
CY2017Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2018Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4002000 USD
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1427000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
818000 USD
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
311000 USD
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
442000 USD
CY2017Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1966000 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13097000 USD
CY2017Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
CY2018Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
11000 USD
CY2017Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2018Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
124000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1539000 USD
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1526000 USD
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
317000 USD
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
317000 USD
CY2018Q1 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
196000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-342753000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345043000 USD
CY2017Q1 us-gaap Revenue From Grants
RevenueFromGrants
324000 USD
CY2018Q1 us-gaap Revenue From Grants
RevenueFromGrants
60000 USD
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
324000 USD
CY2018Q1 us-gaap Sales Revenue Net
SalesRevenueNet
60000 USD
CY2016Q4 us-gaap Security Deposit
SecurityDeposit
307000 USD
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1276000 USD
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1273000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
264000 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
281000 USD
CY2017Q3 us-gaap Share Price
SharePrice
4.00
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2018Q1 us-gaap Short Term Investments
ShortTermInvestments
3991000 USD
CY2017Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
570784 shares
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
27500 shares
CY2017Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
28700000 shares
CY2017Q2 us-gaap Stock Issued During Period Shares Stock Splits
StockIssuedDuringPeriodSharesStockSplits
2900000 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
13502000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
11635000 USD
CY2017Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
10
CY2017Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
65000 USD
CY2018Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
36000 USD
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2839963 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9698726 shares
CY2017Q4 yten Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
489000 USD
CY2018Q1 yten Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
246000 USD
CY2016Q4 yten Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents
7741000 USD
CY2017Q1 yten Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents
5307000 USD
CY2017Q4 yten Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents
14804000 USD
CY2018Q1 yten Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents
7900000 USD
CY2017Q1 yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
23000 USD
CY2018Q1 yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
46000 USD
CY2017Q1 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1109000 USD
CY2018Q1 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1094000 USD
CY2017Q1 yten Increase Decrease In Deferred Rent And Long Term Liabilities
IncreaseDecreaseInDeferredRentAndLongTermLiabilities
-275000 USD
CY2018Q1 yten Increase Decrease In Deferred Rent And Long Term Liabilities
IncreaseDecreaseInDeferredRentAndLongTermLiabilities
-32000 USD
CY2017Q4 yten Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
1005000 USD
CY2018Q1 yten Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
973000 USD
CY2017 yten Operating Leases Landlord Reimbursement For Lease Improvements
OperatingLeasesLandlordReimbursementForLeaseImprovements
889000 USD
CY2017 yten Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments
Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments
444000 USD
CY2018Q1 yten Restructuring Contract Termination Fees Payable
RestructuringContractTerminationFeesPayable
246000 USD
CY2018Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company&#8217;s investment policy which establishes a concentration limit per issuer.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div>
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001121702-18-000016-index-headers.html Edgar Link pending
0001121702-18-000016-index.html Edgar Link pending
0001121702-18-000016.txt Edgar Link pending
0001121702-18-000016-xbrl.zip Edgar Link pending
ex-311x20180331.htm Edgar Link pending
ex-312x20180331.htm Edgar Link pending
ex-321x20180331.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
yten-20180331.xml Edgar Link completed
yten-20180331.xsd Edgar Link pending
yten-20180331x10q.htm Edgar Link pending
yten-20180331_cal.xml Edgar Link unprocessable
yten-20180331_def.xml Edgar Link unprocessable
yten-20180331_lab.xml Edgar Link unprocessable
yten-20180331_pre.xml Edgar Link unprocessable